

VII. BIBLIOGRAFÍA

Ackermann AB, Magaña García M. Naming acquired melanocytic nevi. Unna's, Miescher's, Spitz's, Clark's. *Am J Dermatopathol* 1990; 12: 1983-209.

Ackermann AB, Cavegne BM, Abad-Casin-Tahan, Robinson RJ. Resolving quandaries in Dermatology, Pathology and Dermopathology. Baltimore, Maryland: Prometheus Medical Press. Williams and Wilkins 1995; 169.

AJCC. Malignant melanoma of the skin (excluding eyelid). En: Handbook for staging of cancer. Manual for staging of cancer. 4th ed. Philadelphia: American Joint Committee on Cancer; J.B. Lippicott Company, 1993: 155-160.

AJCC. AJCC Cancer Staging Handbook. 5th ed. Philadelphia: American Joint Committee on Cancer; J.B. Lippicott Company, 1998.

Albert LS, Fewkes J, Bober AJ. Metastatic lentigo maligno melanoma. *J Dermatol Surg Oncol* 1990; 15:56-58.

Albino AP, Vidal MJ, McNutt NS, Shea CR, Prieto VG, Nanus DM, Palmer JM. Mutation and expression of the p53 gene in human malignant melanoma. *Melanoma Res* 1994; 4: 35-45.

Alvarez de Mon Soto M, Camacho Martinez F, Diez Perez JL, Diaz Rubio E, Gonzalez Larriba JL, Guillén Porta JJ, Lopez Lopez JJ, Moreno Nogueira JA, Serrano Ortega S, Toribio Perez J. Panorámica actual del melanoma, Madrid: Acción Médica, 1997.

Ames FC, Balch CM, Reintgen D. Local recurrences and their management. In Balch CM, Houghton AM, Milton GW y cols. Eds. Cutaneous melanoma. 2nd ed. Philadelphia. JB Lippicott, 1992; 287-294.

Argenziano G, Fabroccini G, Carli P et al. Epiluminiscence microscopy for the diagnosis of doubtful melanocytic skin lesions. Comparison of the ABCD rule of dermatoscopy with a new 7 point checklist based on pattern analysis. *Arch Dermatol* 1998; 134: 1563-1570.

Armstrong B. Melanoma incidence in Europe. *Cancer Causes Control* 1996; 7: 195-196.

Armstrong BK. Epidemiology of malignant melanoma: intermittent or total accumulated exposure to the sun?. *J Dermatol Surg Oncol* 1988; 14: 835-849.

Augutsson A. Melanocytic nevi, melanoma and sun exposure. *Acta Dermatol Venereol* 1991; 166 (Supl): 1-34.

Australian Cancer Network. Guidelines for the management of cutaneous melanoma. Sydney: The Stone Press, 1997.

Bachelor H, Flageul B, Degos L, Bounsell L, Beusessan D. TCR y gamma bearing T lymphocytes infiltrating human primary cutaneous melanoma. *J Invest Dermatol* 1992; 98: 369-374.

Baker SA, Fearon ER, Nigro JM. Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. *Science* 1989; 244: 217-221.

Balch CM, Urist MM, Karakousis CP et al. Efficacy of 2 cm margins for intermediate thickness melanomas (1-4 mm) results of multi-institutional randomised surgical trial. *Ann Surg* 1977; 186: 635-642.

Balch CM, Soong S, Shaw H, Urist MM, McCarthy WH. An analysis of prognostic factors in 8500 patients with cutaneous melanoma. In Balch CM, Houghton AN, Milton GW, Sober A, Soong S. *Cutaneous melanoma*. 2nd ed. Philadelphia; Lippincott.,1992; 165-187.

Balch CM, Houghton AN, Peters LJ. Cutaneous melanoma. In; De Vita VT, Hellman S, Rosenberg SA, eds. *Cancer JB*. Lippincott, 1999; 1612-1661.

Balch CM, Buzaid AC, Atkins MB, Cascinelli N, Coit DG, Fleming ID et al. A new American Joint Committee on Cancer staging system for cutaneous melanoma. *Cancer* 2000, 88:1484-91.

Balch CM, Soong SJ, Gershevald JE, Thompson JF, Reintgen DS, Cascinelli N et al. Prognostic factors analysis of 17600 melanoma patients: validation of the american joint comitee on canccer melanoma staging system. *J Clin Oncol* 2001a; 19(16): 3622-3634.

Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG et al. Final version of the AJCC staging system for cutaneous. *J Clin Oncol* 2001b; 19: 3635-3648.

Bale SJ, Greene MH, Lovrien E. Hereditary melanoma, the dysplastic nevus syndrome and transferrin. *Cancer Genets Cytogenet* 1986; 23: 279-286.

Bale SJ, Darcopoli NC, Tucker MA. Mapping the gene for hereditary cutaneous malignant melanoma-dysplastic nevus to chromosome 1p. *N Engl J Med* 1989; 320: 1367-1372.

Ball NJ, Yohn JJ, Morelli JG, Norris DA, Golitz LE, Hoeffler JP. Ras mutations in human melanoma: a marker of malignant progression. *J Invest Dermatol* , 1994; 102: 285-290.

Barnhill RL. Comparison study of familial and non familial melanoma. *Dermatologica* 1992; 184: 2.

Baarnhill RL. Pthology of melanocytic nevi and malignant melanoma. Boston: Bittenworth-Heinemann, 1995.

Barnhill RL, Mihm JR. Histopathology and precursor lesions. In: Balch C, Houghton A, Sober A, Soong S. Cutaneous melanoma. Third edition. St Louis: Quality Med Pub Inc., 1998; 103-133.

Bauchaud JM, Shubinski R, Boussin G et al. Stage I cutaneous malignant melanoma: risk factors and locoregional recurrence after wide local excision and clinical perspectives. *Eur J Surg Oncol* 1992; 18: 442-448.

Baum HP, Meurer I, Unteregger G. Expression of proliferation-associated proteins (proliferating cell nuclear antigen and ki-67 antigen) in Bowen's disease. *Br J Dermatol* 1994; 131: 231-236.

Behars OH, Henson DE, Hutter RVP, Meyers M. American Joint Committee on Cancer manual for staging cancer. Philadelphia: JB Lippincott, 1988.

Beral V, Evans S, Shaw H, Milton G. Oral contraceptive use and malignant melanoma in Australia. *Br J Cancer* 1984; 6:435-440).

Berwick M. Epidemiology. Current trends, risk factors, and environmental concerns. In: Balch C, Houghton A, Sober A, Soong S. Cutaneous Melanoma. Third ed. St Louis: Quality Med Pub Inc, 1998; 551-571.

Bevilacqua RG, Coit DG, Rogatko A et al. Axillary dissection in melanoma: Prognostic variables in node-positive patients. *Ann Surg* 1990; 212: 125-131.

Binder M, Puspoeck Schwartz M, Steiner A, Pehamberger H, Wolff K. Epiluminescence microscopy of small pigmented skin lesions: short-term formal training improves the diagnostic performance of dermatologists. *J Am Acad Dermatol* 1997; 36: 197-292.

Blessing K, Kernohan NM, Park KG. Subungual malignant melanoma: clinicopathological features of 100 cases. *Histopathology*. 1991; 19: 425-429.

Bonfrer JM, Korse CM. Monitoring malignant melanoma with the S100B tumour marker. *Recent Results Cancer Res* 2001; 158: 149-157.

Bouffard D, Barnhill RL, Mihm MC, Sober AJ. Very late metastasis (27 years) of cutaneous malignant melanoma arising in an halo giant congenital nevus. *Dermatology* 1994; 199:162-163.

Bohn M, Moller P, Kalbfleisch U, Czarnecki M, Schadendorf D. Interleukin 7 induces lymphokine-activated killer cell activity against allogenic and autologous melanoma cells. *J Invest Dermatol* 1993; 100: 590.

Braun N, Papadopoulos T, Miller-Hermelink HK. Cell cycle dependent distribution of the proliferation associated ki-67 antigen in human embryonic lung cells. *Virchows Arch B* 1988; 56: 25-33.

Breslow A. Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. *Ann Surg* 1970; 172: 902-908.

Brown CD, Zitelli JA. The prognosis and treatment of true local cutaneous recurrent melanoma. *Dermatol Surg* 1995; 21: 285-290.

Brown M. Standing and prognosis of Melanoma. *Seminars in Cutaneous Medicine and Surgery*. 1997; 16: 113-121.

Brujin JA. Desmoplastic melanoma. *Histopathology* 1992; 20: 197.

Buendia Eisman A, Ortega del Olmo R, Serrano Ortega A. ¿Han cambiado nuestros melanomas?. *Actas Dermosifiliol* 1997; 88: 13-17.

Butow PN, Kazemi JN, Beeney LJ, Griffin AM; Dunn SM, Tattersall MH. Medical Psychology Unit, Department of Medicine, University of Sidney, Australia. When the diagnosis is cancer: patient communication experiences and preferences. *Cancer* 1996; 77: 2630-2637.

Buttner P, Garbe C, Bertz J, Burg G, D'Hoedt B, Drepper H, Guggenmoos-Holzmann I, Lechner W, Lippold A, Orfanos CE. Primary cutaneous melanoma. Optimized cutoff points of tumor thickness and importance of Clark's level for prognostic classification. *Cancer* 1995; 15: 75: 2499-2506.

Buzaid AC, Ross MI, Balch CM, Soong S, McCarthy WH, Tinoco L et al. Critical analysis of the current American Joint Committee on Cancer staging system for cutaneous melanoma and proposal for a new staging system. *J Clin Oncol* 1997; 15: 1039-1051.

Calvin A, Ridgeway MD, Tina J, Hieken MD, Salve G, Ronan MD. Acral lentiginous melanoma. *Arch Surg* 1995; 130: 88-92.

Carli P, Massi D, Santucci M, Biggeri A, Gianotti B. Cutaneous melanoma histologically associated with a nevus and melanoma de novo have a different profile of risk: Results from a case-control study. *J Am Acad Dermatol* 1999; 40: 549-557.

Carrillo E. Análisis mediante RT-PCR de la enzima tirosinasa en sangre periférica de pacientes con melanoma. Prueba para la evaluación de la evolución de la enfermedad. Tesis Doctoral. Universidad de Granada, 1999.

Carrillo E, Marchal JA, Prados J, Melguizo C, Velez C, Arena N, Alvarez L, Serrano S, Aránega A. Optimization of the tyrosinase mRNA probe to detect circulating melanocytes with reverse transcription and polymerase chain reaction. *Cell Mol Biol* 1998; 44: 1247-1252.

Castel T, Baradad M, Estapé J. Melanoma maligno. *Jano* 1991; 40: 1441-1508.

Cattoretti G, Becker MH, Key G, Duchrow M, Schluter C, Galle J, Gerdes J. Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. *J Pathol* 1992; 168:357-63.

Clark WH Jr, From L, Bernardino EA, Mihm MC. The histogenesis and biologic behaviour of primary human malignant melanoma of the skin. *Vancer Res* 1969; 705-727.

Clark WH, Elder DE, Guerry D IV, Braitman LE, Trock BJ, Schultz D et al. Model predicting survival in stage I melanoma based on tumor progression. *J Natl Cancer Inst* 1989; 81: 1893-904.

Cohen LM. Lentigo maligna and lentigo malignamelanoma. *J Am Acad Dermatol*, 1995; 33: 923-932.

Cooke KR, Fraser J. Migration and death for malignant melanoma. *Int J Cancer* 1985; 36:175-178.

Creagan ET: Regional and systemic strategies for metastatic malignant melanoma. *Mayo Clin Proc*, 1989; 64: 852-860.

Cress RD, Holly EA. Incidence of cutaneous melanoma among non-hispanic whites, hispanics, asians and blacks: an analysis of California Cancer Registry data 1988-1993. *Cancer Causes Control* 1997; 8:246-252.

Cristofolini M, Franceschi S, Tasin L, Zumiani G, Piscioli F, Talamini R et al. Risk factors for cutaneous malignant melanoma in a northern italian population. *Int J Cancer* 1987; 39: 150-154.

Crombie IK. Distribution of malignant melanoma of the body surface. *Br J Cancer* 1981; 43: 843-849.

Cutler C, Foulkes WD, Brunet JS, Flabbers TY, Shibata H, Narod SA. Cutaneous malignant melanoma in women is uncommonly associated with a family history of melanoma in first-degree relatives: a case-control study. *Melanoma Res* 1996; 6: 435-440.

Day CL, Harrist TJ, Lew RA, Mihm MC. Classification of malignant melanoma according to the histologic morphology of melanoma nodules. *J Dermatol Surg Oncol* 1992; 8: 874-875.

Del Prete SA, Maurer LH, O'Donnell J. Combination chemotherapy with cysplatin, carmustine, dacarbazine and tamoxifen in metastatic melanoma. *Cancer Treat Rep*, 1984; 68: 1403-1405.

Devesa SS, Silverman BT, Young UL et al. Cancer incidence and mortality trends among whites in the US 1947-84. *J Natl Cancer Inst* 1987; 79: 701-777.

Driscoll MS, Grin-Jorgensen CS; grant-Kels JM. Does pregnancy influence the prognosis of malignant melanoma?. *J Am Acad Dermatol* 1993; 29:619-630.

Duncan LM, Travers RL, Koerner FC, Mihm CR, Sober AJ. Estrogen and progesterone receptor analysis in pregnancy-associated melanoma: absence of immunohistochemically detectable hormone receptors. *Human Pathol* 1994; 25: 36-41.

Du Manoir S, Guillaud P, Camus E, Seigneurin D, Brugal G. Ki-67 labeling in postmitotic cells defines different ki-67 pathways within the 2c compartment. *Cytometry* 1991; 12: 455-463.

Eeles RA, Warren W, Knee W, Bartek J, Averill D, Stratton MR, et al. Constitutional mutation in exon 8 of the p53 gene in a patient with multiple primary tumours: molecular and immunohistochemical findings. *Oncogene* 1993; 8: 1269-1276.

Egbert B. Desmoplastic malignant melanoma: a clinico-pathologic study of 25 cases. *Cancer* 1986; 62: 2033-2038.

Einspahr J, Alberts DS, Aickin M, Welch K, Bozzo P, Groogan T, Nelson M. Expression of p53 protein in actinic keratoses, adjacent, normal appearing and non sun exposed human skin. *Cancer Epidemiol Biomarkers Prev*, 1997; 6: 583-587.

Elwood JM, Lee JAH, Walter SD, Mo T, Green AES. Relationship of melanoma and other skin cancer mortality to latitude and ultraviolet radiation in the United States and Canada. *Int J Epidemiol* 1974; 3: 325-332.

Elwood JM. Melanoma and sun exposure. *Semin Oncol* 1996, 23: 650-666.

Elwood JM, Whitehead SM, Davison J, Stewart M, Galt M. Malignant melanoma in England: risk associated with naevi, freckles, social class, hair, colour and sunburn. *Int J Epidemiol* 1990; 19: 801-810.

Essner R, Kuo KT, Wang F, Wen DR, Turner R, Nguyen T, Hoon DSB. Prognostic implications of p53 overexpression in cutaneous melanoma from sun exposed and non-exposed sites. *Cancer* 1998; 82: 309-316.

Evans GRD, Manson PN. Review and current perspectives of cutaneous malignant melanoma. *J Am Coll Surg* 1994; 178: 253-259.

Fearfield LA, Rowe A, Francis N, Fisher C, Gore ME, Bunker CB. Clinico-pathological features of relapsing very thin melanomas. *Clin Exp Dermatol* 2001; 26: 686-695.

Fernandez Pugnaire MA, Ortega del Olmo RM, Serrano Ortega S. Microscopia de Epiluminiscencia en el diagnóstico de los tumores pigmentados (I). *Piel* 1995; 10: 203-209.

Fernandez Pugnaire MA, Ortega del Olmo RM, Serrano Ortega S. Microscopia de Epiluminiscencia en el diagnóstico de los tumores pigmentados (II). *Piel* 1995; 10: 322-325.

Field JK, Pavelic ZP, Spandidos DA, Stambrook PJ, Jones AS, Gluckman JL. The role of the p53 tumor suppressor gene in squamous cell carcinoma of the head and neck. *Arch Otolaryngol Head Neck Surg* 1993; 119: 1118-1122.

Florence VA, Oyjord T, Holm R, Skrede H, Borresen AL, Nesland JM et al. TP53 allele loss, mutation and expression in malignant melanoma. *Br J Cancer* 1994; 69: 253-259.

Gallagher RP, Elwood JM, Hill GB, Coldman AJ, Threfall WJ, Spinelli JJ. Reproductive factors, oral contraceptives and risk of malignant melanoma. Western Canada Melanoma Study. *Br J Cancer* 1985; 52: 901-907.

Geller AC, Miller DR, Lew RA, Clapp RW, Wenneker MB, Koh HK. Mortality of cutaneous melanoma among lower socioeconomic status in Massachusetts. *Am J Public Health* 1996; 86: 538-544.

Gerdes J, Schwab U, Lemke H, Stein H. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. *Int J Cancer* 1983; 31: 13-20.

Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H. Cell cycle analysis of a cell proliferation associated human nuclear antigen defined by the monoclonal antibody Ki-67. *J Immunol* 1984; 133: 1710-1715.

Gerdes J, Li C, Schuster C, Duchrow M, Wohlenberg C, Gerlach C, Stahmer I, et al. Immunobiochemical and molecular biologic characterization of the cell proliferation-associated nuclear antigen that is defined by monoclonal antibody ki-67. *Am J Pathol* 1991; 138: 867-873.

Gerhard DS, Dracopoli NC, Bale SJ, Houghton AN, Watkins P, Payne CE, et al. Evidence against H-ras 1 involvement in sporadic and familial melanoma. *Nature* 1987; 325: 73-81.

Godellas CV, Berman CG, Lyman G, Cruse CW, Rapaport D, Séller R, Wang X, Glass F, Fenske N, Messina J. The identification and mapping of melanoma regional nodal metastases: minimally invasive surgery for the diagnosis of nodal metastases. *Am Surg* 1995; 61: 97-101.

Goodman KJ, Bible ML, London S, Mack TM. Proportional melanoma incidence and occupation among white males in Los Angeles County /California, United States. *Cancer Causes Control* 1995; 6: 451-459.

Gordon LG, Lowry WS, Pedlow PJ, Patterson CC. Poor prognosis for malignant melanoma in Northern Ireland: a multivariate analysis. *Br J Cancer* 1991; 63: 283-286.

Green A. Sun exposure and the risk of melanoma. *Australas J Dermatol* 1984; 25: 99-102.

Greene MH, Clark WH Jr, Tucker MA, Elder DE, Kraemer KH, Fraser MC et al. Acquired precursor of cutaneous malignant melanoma: the familial dysplastic nevus syndrome. *N Engl J Med* 1985; 312: 91-97.

Grin Jorgensen CM, Rigel DS, Friedman RJ. The worldwide incidence of malignant melanoma. En: Balch CM, Houghton AN, Milton GW, Sober AJ, Soong S, editores. Cutaneous melanoma. Filadelfia. Lippincott 1992; 27-39.

Grobb JJ, Gouvernet J, Aymar D, Mostaque A, Romano MH, Collet AM et al. Count of benign melanocytic nevi as a major indicator of risk for nonfamilial nodular and superficial sprading melanoma 1990; 66: 387-395.

Guillaud P, du Manoir S, Seigneurin D. Quantification and topographical description of ki-67 antibody labelling during the cell cycle of normal fibroblastic (MRC-5) and mammary tumour cell lines (MCF-7). *Anal Cell Pathol* 1989; 1: 25-39.

Hafstrom L, Rudestam CM, Blomquist E et al. Regional hypertermic perfusion with melphalan after surgery for recurrent malignant melanoma of the extremities. *J Clin Oncol*, 1991; 9: 209-214.

Handley WS. The pathology of melanotic growths in relation to their operative treatment. *Lancet* 1907; 1: 927-96.

Hall PA, Mckee PH, Menage HP, Dever R, Lane DP. High levels of p53 protein in UV-irradiated normal human skin. *Oncogene* 1993; 8: 203-207.

Hara H, Walsh N, Yamada K. High plasma level of a eumelanin precursor. 6 hydroxy 5 methoxyindole 2 carboxylic acid as a prognostic marker for malignant melanoma. *J Invest Dermatol* 1994, 102-105.

Harris CC. p53: At the crossroads of molecular carcinogenesis and risk assessment. *Science* 1993; 262: 1980-1981.

Harrist TJ, Rigel DS, Day CL; Sober AJ, Lew RA, Rhodes AR. Microscopic satellites are more highly associated with regional lymph node metastasis than in primary melanoma thickness. *Cancer* 1984; 53: 2183-2187.

Hartmann A, Blaszyk H, Cunningham JS, McGovern RM, Schroeder JS, Helander SD, Pittelkow MR, Sommer SS, Kovach JS. Overexpression and mutations of p53 in metastatic malignant melanomas. *Int J Cancer* 1996;67:313-7.

Heenan PJ, English DR, Holman CD, Armstrong BK. Survival among patients with clinical stage I cutaneous malignant melanoma diagnosed in Western Australia in 1975/1976 abd 1980/1981. *Cancer* 1991; 68: 2079-2087.

Hemo Y, Gutman M, Klasner JM. Anatomic site of primary melanoma is associated with depth of invasion. *Arch Surg* 1999; 134: 148-150.

Henriksen K, Stames K, Volden G, Falk ES. Ultraviolet radiation at high latitudes and the risk of the skin cancer. *Photodermatology* 1989; 6: 110-117.

Henrique R, Azevedo R, Bento MJ, Domingues JC, Silva C, Jeronimo C. Prognostic value of Ki-67 expression in localized cutaneous malignant melanoma. *J Am Acad Dermatol* 2000; 43: 991-1000.

Hoffman B, Lierberman DA. Molecular controls of apoptosis: differentiation/growth arrest primary response genes, proto-oncogenes, and tumor suppressor genes as positive and negative modulators. *Oncogene* 1994; 9: 1807-1812.

Holman CD, Armstrong BK. Pigmentary traits origin, benign nevi nad family history as risk factors for cutaneous malignant melanoma. *J Natl Cancer Inst* 1984; 72:257-266.

Holman CD, Armstrong BK, Heenan PJ. Cutaneous malignant melanoma in women. Exogenous sex hormones and reproductive factors. *Br J Cancer* 1984; 50: 673-680.

Holman CDJ, Armstrong BK, Heenan PJ. Relationship of cutaneous malignant melanoma to individual sunlight-exposure habits. *J Natl Cancer Inst* 1986; 76:403-414.

Holly EA, Weiss NS, Liff JM. Cutaneous melanoma in relation to exogenous hormones and reproductive factors. *J Natl Cancer Inst* 1983; 70:827-831.

Holly EA, Aston DA, Cress RD, Ahn DK, Kristiansen JJ. Cutaneous melanoma in women II. Phenotypic characteristics and other host-related factors. *Am J Epidemiol* 1995; 141: 934-942.

IARC. European Network of Cancer Registries. EUROCIM User Manual, 2nd. Ed. International Agency for Research on Cancer (IARC), Lyon, 1995.

Jaros E, Perry RH, Adam L, Kelly PJ, Crawford PJ, Kalbag RM et al. Prognostic implications of p53 protein, epidermal growth factor receptor and ki-67 labelling in brain tumours. *Br J Cancer* 1992; 66: 373-385.

Jelfs PL, Coates M, Giles G et al. Cancer in Australia 1989-1990 (with projections to 1995). Cancer series n°5. Australian institute of Health and Welfare and Australasian Associations of cancer registries. Canberra.

Johnson JP, Stade BG, Holzmann B, Schwable W, Riehmüller G. De novo expression of intercelular adhesion moleculae in melanoma correlates with increased risk of metastasis. *Proc Natl Acad Sci USA*, 1989; 86: 641-648.

Jonhson TM, Smith JW, Nelson RF, Chang A. Current therapy for cutaneous melanoma. *J Am Acad Dermatol* 1995; 32: 689-707.

Kadonaga JN, Frieden IJ. Neurocutaneous melanosis: Definition and review of the literature. *J Am Acad Dermatol* 1991; 32: 689-707.

Kaleem Z, Lind AC, Humphrey PA, Sueper RH, Swanson PE, Ritter JH, Wick MR. Concurrent Ki-67 and p53 immunolabelling in cutaneous melanocytic neoplasms: an adjunct for recognition of the verticak growth phase in malignant melanomas?. *Mod Pathol* 2000; 13: 217-222.

Karjalainen JM, Eskelinen MJ, Kellokoski JK, Reinikainen M, Aihava EM, Kosma VM. P21 (WAF1/CIP1) expression in stage I cutaneous malignant melanoma: its relationship with p53, cell proliferation and survival. *Br J Cancer*, 1999; 79: 895-902.

Kashani Sabet M, Sagebiel SW, Ferreira CMM, Nosrati M, Miller III JR. Vascular involvement in the prognosis of primary cutaneous melanoma. *Arch Dermatol* 2001; 137: 1169-1173.

Kaudewitz P, Braun-Falco O, Ernst M, Landthaler M, Stolz W, Gerdes J. Tumor cell growth fractions in human malignant melanomas and the correlation to histopathologic tumor grading. *Am J Pathol* 1989;134:1063-8.

Kelley JN, Sagebiel RW, Aaclderon W et al. The frequency of local recurrence and microsatelitoses as a guide to re-excision margins for cutaneous malignant melanoma. *Ann Surg* 1984; 200: 759-763.

Kern SE, Fearon ER, Kasper W, Tersmette MD, Enterline JP, Leppert M. Allelic loss in colorectal carcinoma. *JAMA* 1989; 261: 3099-3103.

Kerschmann RL, McCalmont TH, Le Boit PE. Expresión de la oncoproteína p53 e índice de proliferación en el queratoacantoma y el carcinoma escamoso. *Arch Dermatol* 1994; 130: 181-186.

Kiene P, Petres-Dunsche C, Folster Holst R. Pigmented pedunculated malignant melanoma. A rare variant of nodular melanoma. *Br J Dermatol* 1995; 133: 300.

Kirkwood JM, Strawderman MH, Ernstoff MS et al. Interferon alfa 2b adjuvant therapy of high risk resected cutaneous melanoma. The Eastern Cooperative Oncology Group trial EST, 1684. *J Clin Oncol* 1996; 14: 7-17.

Kittler H, Pehamberger H, Wolff K, Binder M. Follow-up of melanocytic skin lesions with digital epiluminescence microscopy: patterns of modifications observed in early melanoma, atypical nevi, and common nevi. *J Am Acad Dermatol* 2000;43:467-76.

Koch HK. Cutaneous melanoma. *N Engl J Med* 1991; 325: 171-182.

Kopf AW. Prognostic index for malignant melanoma. *Cancer* 1987; 59: 1236.

Kuchelmeister C, Schaumburg-Lever G, Garbe C. Acral cutaneous melanoma in caucasians: clinical features, histopathology and prognosis in 112 patients. *Br J Dermatol* 2000; 143(2): 275-280.

Lamb P, Crawford LV. Characterization of the human p53 gene. *Mol Cell Biol* 1986; 6: 1379-1385.

Lane DP, Crawford LV. T antigen is bound to a host protein in SV40-transformed cells. *Nature* 1979; 278: 261-263.

Lane DP. The regulation of p53 function. *Int J Cancer* 1994; 57: 623-627.

Lane DP. On the expression of the p53 protein in human cancer. *Mol Biol Rep* 1994; 19: 23-29.

Langley RGB, Fitzpatrick TB, Sober AJ. Clinical characteristics. In: Blach C, Houghton A, Sober A, Soong S. Cutaneous melanoma. Third Ed. St Louis: Quality Med Pub Inc., 1998; 81-101.

Leon P, Daly JM, Synnestvedt M; Schults DJ, Elder DE, Clark WH Jr. The prognostic implications of microscopic satellites in patients with clinical stage I melanoma. Arch Surg 1991; 126: 1461-1468.

Lever K. Histopathology of the skin. 5th Ed. Lippincott, New York, 1983.

Levine AJ, Perry ME, Chang A. The role of the p53 tumour-suppressor gene in tumor genesis. Br J Cancer 1994; 69:409-416.

Li N, Mangini J, Bhawan J. New prognostic factors of cutaneous melanoma: a review of the literature. J Cutan Pathol 2002; 29: 324-340.

Lieber KA, Standiford SB, Kuvshinoff BW, Ota DM. Surgical management of aberrant sentinel lymph node drainage in cutaneous melanoma. Surgery 1998; 124: 757-761.

Longstreth JD. Melanoma genesis. Putative causes and possible mechanisms. In Blach C, Houghton A, Sober A, Soong S. Cutaneous melanoma. 3rd edition. St Louis. Quality Med Pub Inc, 1998; 535-550.

Lopez Nevot MA, Garcia E, Parejo E, Bonal J, Martín J, Ruiz Cabello F, Serrano Ortega S, Garrido F. Differential expression of HLA class I and II antigens in primary and metastatic melanomas. J Immunogenetics, 1986; 13: 219-227.

Lubbe J, Reichel M, Burg G, Kleihues P. Absence of p53 gene mutation in cutaneous melanoma. J Invest Dermatol 1994; 102: 819-821.

Mackie RM, Aichinson T. Severe sunburn and subsequent risk of primary cutaneous malignant melanoma in Scotland. Br J Cancer 1982; 46: 955-960.

Mackie RM. Cancer of skin. Ed Martin Dunitz, Singapore, 1989.

Mackie RM. Clinical recognition of early invasive malignant melanoma: looking for changes in size, shape and color is successful. Br Med J 1990; 301: 1005-1006.

Mackie RM, Mc Henry O, Hole D. Accelerated detection with prospective surveillance for cutaneous malignant melanoma in high risk groups. Lancet 1993; 341: 1618-1620.

Mackie RM, Hole DJ. Incidence and thickness of primary tumors and survival of patients with cutaneous malignant melanoma in relation to socioeconomic status. Br Med J 1996; 312: 1125-1128.

McCarthy WH, Shawn HM: The surgical treatment of primary melanoma. Hematology/Oncology Clinics of North America. 1998; 4: 793-799.

McMaster KM, Edwards MJ, Ross M. Letter to the editor. *N Engl J Med* 1999; 340: 318-319.

Malvey J, Puig S, Martí R, Castel T, Mascaró JM. Melanoma maligno cutáneo (I): Epidemiología, patogenia y diagnóstico. *Med Cutan Iber Lat Am*. Vol XXVI/98: 283-289.

Marcoval J, Moreno A, Graells J, Vidal A, Escriba JM, Garcia Ramirez M, Fabra A. Angiogenesis and malignant melanoma . Angiogenesis is related to the development of vertical (tumorigenic) growth phase. *J Cutan Pathol* 1997; 24: 212-218.

Martín Casañez E. Melanoma maligno. Factores de pronóstico clínico. Tesis Doctoral, 1997.

Mascaró J, Molgó M, Castel T, Castro J. Plasma cells within the infiltrate of primary cutaneous melanoma of the skin: a confirmation of its histoprognotic value. *Am J Dermatopathol* 1987; 9: 497-499.

Massi D, Carli P, Frachi A, Santucci M. Nevus associated melanomas: cause or chance?. *Melanoma Res* 1999; 9(1): 85-91.

Maxwell KJ, Elwood JM. W radiation from fluorescents lights. *Lancet* 1983; 2: 579-583.

Melia J, Frost T, Graham-Brown R. Problems with registration of malignant melanoma in England. *Br J Cancer* 1995; 72: 224-228.

Mellado B, Colomer D, Castel T et al. Detection of circulating neoplastic cells by reverse transcriptase polymerase chain reaction in malignant melanoma. Association with clinical stage and prognosis. *J Clin Oncol* 1996; 14: 2091-2097.

Menzies SW, Ingvar C, Crotty KA, McCarthy WH. Frequency and morphologic characteristics of invasive melanomas lacking specific surface microscopic features. *Arch Dermatol* 1996; 132: 1178-1182.

Merimsky O, Inbar M, Gerard B, Chaintchik S. Fotoemustine an advance in the treatment of metastatic malignant melanoma. *Melanoma Res*, 1992, 2: 401-406.

Mitchell MS, Kan-Mitchell J, Kempf RA et al. Active specific immunotherapy for melanoma: Phase I trial of allogeneic lysates and a novel adjuvant. *Cancer Res*, 1988; 48: 5883-5893.

Mohr P, Makki A, Breitbart E, Shadendorf D. Combined treatment of stage IV melanoma patients with amifosfina and fotoemustine a pilot study. *Melanoma Res* 1998; 8: 166-169.

Montano X, Shamsheer M, Whitehead P, Dawson K, Newton J. Analysis of p53 in human cutaneous melanoma cell lines. *Oncogene* 1994; 9: 1455-1459.

Moretti S, Massobrio R, Brogelli L, Novelli M, Giannotti B, Bernengo MG. Ki67 antigen expression correlates with tumor progression and HLA-DR antigen expression in melanocytic lesions. *J Invest Dermatol* 1990;95:320-4.

Moretti S, Martini L, Pinzi C, Cecca E, Ganotti B, Berti E. Pattern of integrin expression changes in human benign vs. malignant melanocytic lesions. *J Invest Dermatol* 1992; 98: 369-374.

Moretti S, Pinzi C, Spallanzani A, Berti E, Chiarugi A, Mazzoli S, Fabiani M, Vallecchi C, Herlyn M. Immunohistochemical evidence of cytokine networks during progression of human melanocytic lesions. *Int J Cancer* 1999; 84:160-8.

Moretti S, Spallanzani A, Chiarugi A, Fabiani M, Pinzi C. Correlation of Ki-67 expression in cutaneous primary melanoma with prognosis in a prospective study: different correlation according to thickness. *J Am Acad Dermatol* 2001; 44:188-92.

Morton DL, Wen DR, Wong JH et al. Technical details in intraoperative lymphatic mapping for the early stage melanoma. *Arch Surg* 1992; 127: 392-399.

Morton DL, Wen DR, Foshag LJ et al. Intraoperative lymphatic mapping and selective cervical lymphadenectomy for early stage melanomas of the head and the neck. *J Clin Oncol* 1993; 11: 1751-1756.

Moyhahan GD. The 3Cs of melanoma: Time for a change?. *J Am Acad Dermatol* 1994; 30: 510.

Mowat M, Cheng A, Kimura N, Berstein A, Benchimol S. Rearrangement of the cellular p53 gene in erytroleukemia cells transformed by Friend virus. *Nature* 1985; 324: 633-636.

Newton JA. Genetics of the melanoma. *Br Med Bull* 1994; 50: 677- 687.

NIH-1992. Diagnosis and treatment of early melanoma. NIH Consensus Statement 1992; 10: 1-26.

Ordoñez Gallego A, Feliu Battle J, Rodríguez García JM, García Barón M. Factores pronósticos. En: Gonzalez Barón M, Ordoñez Gallego A. *Melanoma*. Barcelona, Masson SA, 1998; 125-147.

Oren M, Levine AJ. Molecular cloning of a cDNA specific for the murine p53 cellular tumor. *Proc Natl Acad Sci USA* 1983; 80: 56-59.

Osborne JE, Hutchinson PE. Clinical correlates of Breslow thickness of malignant melanoma. *Br J Dermatol* 2001; 144: 476-483.

Osterlind A, Tucker MA, Stone BJ, Jensen OM. The Danish case-control study of cutaneous malignant melanoma. I Importance of host factors. *Int J Cancer* 1988; 42: 200-206.

Ostmeier H, Fuchs B, Otto F et al. Can immunohistochemical markers and mitotic rate improve prognostic precision in patients with primary melanomas?. *Cancer* 1999; 85: 2391-2399.

Ostmeier H, Suter L. The KI-67 antigen in primary human melanomas. Relationship to mitotic rate and tumor thickness and its stability. *Arch Dermatol Res* 1989; 281: 173-177.

Parker SL, Tong T, Bolden S. Cancer statistics, 1996. *CA Cancer J Clin* 1996; 65: 5-27.

Patel JK, Didolka MS, Pickren JW, Moore RH. Metastatic pattern of malignant melanoma. *Am J Surg*, 1978, 135: 807-810.

Platz A, Hansson J, Ringborg U. Screening of germline mutations in the CDK4, CDKN2C and TP53 genes in familial melanoma: a clinic-based population study. *Int J Cancer* 1998;78:13-5.

Parkin DM, Muir CS, Whelan SL, Gao YT, Ferlay J, Powell J. Editores. Cancer incidence in five continents. Vol VI Lyon IARC Scientific Publication 1992, 120.

Parkin DM, Whelan SL, Ferlay J, Raymond L, Young J. Eds. Cancer incidence in five continents. Vol VII. Lyon: IARC Scientific publication 1997, 143.

Pehamberger H, Steiner A, Wolff K. In vivo epiluminescence microscopy of the pigmented skin lesions. I. Pattern analysis of pigmented skin lesions. *J Am Acad Dermatol* 1987; 17: 571-583.

Piepkorn M, Meyer LJ, Goldgar D. The dysplastic melanocytic nevus: a prevalent lesion that correlates poorly with clinical phenotype. *J Am Acad Dermatol* 1989; 20: 407-415.

Porras BH, Cockerell CJ. Cutaneous malignant melanomas: Classification and clinical diagnosis. *Seminars in Cutaneous Medicine and Surgery*, 1997; 16: 88-96.

Puig L, Alegre M, Costa I, Matías-Guiu X. Overexpression of p53 in disseminated superficial actinic porokeratosis with and without malignant degeneration. (carta). *Arch Dermatol* 1995; 131: 353.

Ramsay JA, From L, Iscoe NA, Kahn HJ. MIB-1 proliferative activity is a significant prognostic factor in primary thick cutaneous melanomas. *J Invest Dermatol* 1995;105:22-6.

Retsas S, Henry K, Mohammed MQ, McCrae K. Prognostic factors of cutaneous melanoma and a new staging system proposed by the American Joint Committee on Cancer (AJCC): validation in a cohort of 1284 patients. *Eur J Cancer* 2002; 38: 511-516.

Reitgen DS, Cox C, Singluff CL et al. Recurrent malignant melanoma: The identification of prognostic factors to predict survival. *Ann Plast Surg* 1992; 28: 45.

Reintgen DS, Brobeil A. Lymphatic mapping and selective lymphadenectomy as a alternative to elective lymph node dissection in patients with malignant melanoma. *Hematol Oncol Clin North Am* 1998; 12: 807-821.

Rhodes AR, Melski JW. Small congenital nevocelular nevi and the risk of cutaneous melanoma. *J Pediatr* 1982; 100: 219-224.

Rhodes AR, Weinstock MA, Fitzpatrick TB. Risk factors for cutaneous melanoma: A practical method of recognizing predisposed individuals. *JAMA* 1987; 258: 3146-3154.

Rieger E, Soyer HP, Garbe C, Büttner P, Kofler R, Weiss J et al. Overall and site-specific risk of malignant melanoma associated with nevus counts as different body sites: a multicenter case control study of the German Malignant Melanoma Registry. *Int J Cancer* 1995; 62: 393-397.

Rigel DS, Friedman RF, Kopf AW. Factor influencing survival in melanoma. *Dermatol Clin* 1991; 9: 633-642.

Rigel DS, Friedman RJ, Kopf AW. The incidence of malignant melanoma in the United States: issues as we approach the 21st century. *J Am Acad Dermatol* 1996; 34:839-847.

Rinne D, Baun RP, Hor G, Kaufmann R. Primary staging and follow-up of high risk melanoma patients with whole-body 18F-fluorodeoxyglucose positron emission tomography: results of a prospective study of 100 patients. *Cancer* 1998; 82: 1664-1671.

Ródenas López JM. Factores de riesgo en el melanoma maligno cutáneo. Tesis doctoral. Granada. Universidad de Granada. 1994.

Rodenas JM, Delgado Rodriguez M. Factores de riesgo en el melanoma cutáneo en una población del sur de España. *Actas Dermosifiliogr* 1996a; 87(243-252).

Ródenas JM, Delgado-Rodriguez M, Herranz MT, Tercedor J, Serrano S. Sun exposure, pigmentary traits and risk for cutaneous malignant melanoma: a case-control study in Mediterranean population. *Cancer Causes Control* 1996b; 7:275-283.

Ródenas JM, Delgado Rodriguez M, Fariñas Alvarez MC, Herranz MT, Serrano S. Melanocytic nevi and risk of cutaneous malignant melanoma in southern Spain. *Am J Epidemiol* 1997; 145: 1020-1029.

Rodenas López JM. Factores de riesgo del melanoma cutáneo (I). Factores de riesgo individuales: Rasgos pigmentarios. *Piel* 1998a; 13: 437-445.

Rodenas López JM. Factores de riesgo del melanoma cutáneo (II). Factores de riesgo individuales: Nevus melanocíticos. *Piel* 1998b; 13: 491-499.

Ródenas López JM. Factores de riesgo del melanoma cutáneo (III). Factores de riesgo ambientales: luz solar. *Piel* 1999c; 14: 10-16.

- Rogers GS, Braun SM, Prognostic factors. *Dermatol Clin* 2002; 20: 647-658.
- Rosenberg L, Goldstein J, Ben Yahar Y et al. The pedunculated malignant melanoma. *J Dermatol Surg Oncol* 1981; 7: 123.
- Ruiz Maldonado R, Orozco Covarrubias ML. Abordaje y tratamiento de los nevos melanocíticos. *Arch Dermatol* 1999; 10:140-148.
- Saez Castresana J. Bases genéticas y moleculares. En: Gonzalez Barrón M, Ordóñez Gallego A. *Melanoma*. Barcelona; Masson, 1998: 43-57.
- Salvatella N, Moragas JM. Melanomas. *Monogr Dermatol* 1989; 2: 351-392.
- Schmoeckel C, Braun Falcó O: Prognostic index in malignant melanoma. *Arch Dermatol* 1978; 114(6): 871-876.
- Schoultz E, Hansson LO, Djureen E et al. Prognostic value of serum analices of S-100 beta protein in malignant melanoma. *Melanoma Res* 1996; 6: 133-137.
- Schreiber MM; Bozzo PD, Moon TE. Malignant melanoma in southern Arizona: Increasing incidence and sunlight as an etiologic factor. *Arch Dermatol* 1981; 117: 6-11.
- Schutcher L, Schultz DJ, Synnestvedt M et al. A prognostic model predicting ten years survival in patients with primary melanoma based on readily available clinical and histologic attributes. *Ann Intern Med* 1996; 125: 368-375.
- Serrano S, Ortega del Olmo R, Linares J. Malignant Blue nevus. *Skin Cancer*; 1986: 4:309-313.
- Serrano S, Ortega R, Trujillo J. Utilidad de la epiluminiscencia en el diagnóstico diferencial entre melanomas malignos y nevus pigmentocelulares. *Actas Dermosifiliol* 1989; 80: 866-868.
- Serrano Falcón MM. *Melanoma de Cabeza y Cuello*. Tesis Doctoral, Granada, 2001.
- Serrano S, Ortega del Olmo R, Buendia Eisman A. Metastasis demoradas de melanoma maligno. *Actas Dermosifiliol* 1987; 78: 687-689.
- Skelton HG, Maceira J, Smith KJ, McCarthy WF, Lupton GP, Garham JH. HMB45 negativve spindle celll malignant melanoma. *Am J Dermopathol* 1997; 19: 580-584.
- Skender-Kalnenas TM, English DR, Heenan PJ. Benign melanocytic lesions risk markers or precursors of cutaneous melanoma. *J Am Acad Dermatol* 1995; 33: 1000-1007.
- Shaw JHF, Koea JB. Acral melanoma in Auckland. *Br J Surr* 1998; 75: 69-72.

Shea TC, Antman KH, Eder JP et al. Malignant melanoma: treatment with high dose combination alkylating agent chemotherapy and autologous bone marrow support. *Arch Dermatol* 1988; 124: 878-884.

Slootweg PJ, Koole R, Hordisk GJ. The presence of p53 protein in relation to ki-67 as cellular proliferation marker in head and neck squamous cell carcinoma and adjacent dysplastic mucosa. *Eur J Cancer* 1994; 30: 138-141.

Smolle J. Biological significance of tumor thickness. Theoretical considerations based on computer simulation. *Am J Dermatopathol* 1995; 17: 281-286.

Smolle J, Okcu A, Hofmann-Wellenhof R, Pfaffenthaler E, Fink-Puches R, Richtig E, Kerl H. Automated measurement of melanoma cross-sectional area. *Am J Dermatopathol* 1998; 20(2): 155-159.

Sober AJ, Fitzpatrick TB, Mihm MC et al. Early recognition of cutaneous melanoma. *J Am Acad Dermatol* 1979; 242: 2795-2799.

Sober AJ. Epidemiology of cutaneous melanoma. *Dermatol Clin* 1991; 9:617.

Soini Y, Kamel D, Lehto VP, Oikarinen A, V'kangas K. Aberrant accumulation of p53 associates with ki-67 and mitotic count in benign skin lesions. *Br J Dermatol* 1994; 131: 514-520.

Soyer HP. Ki67 immunostaging in melanocytic skin tumors. Correlation with histological parameters. *J Cutan Pathol* 1991; 18: 264-272.

Spandau DF. Distinct conformations of p53 are observed at different stages of keratinocyte differentiation. *Oncogene* 1994; 9: 1861-1868.

Spencer CA, Groudine M. Control of c-myc regulation in normal and neoplastic cell. *Adv Cancer Res*, 1991; 56: 1-48.

Spitz S. Melanomas of childhood. *Am J Pathol* 1948; 24: 591-609.

Stadelmann WK, Reintgen DS. Prognosis in malignant melanoma. *Hematol Oncol Clin North Am* 1998; 12:767-96.

Stadler R, Garbe C, Hautklinik, Minden. Nevus associated malignant melanomas- diagnostic validation and prognosis. *Hautarzt* 1991; 42: 424-429.

Stoltz W, Riemann A, Cognetta A et al. ABCD rule of dermoscopy: a new practical method for early recognition of malignant melanoma. *Eur J Dermatol* 1994; 4:521-527.

Straume O, Akslen LA. Alterations and prognostic significance of p16 and p53 protein expression in subgroups of cutaneous melanoma. *Int J Cancer* 1997; 74: 535-539.

Straume O, Sviland L, Akslen LA. Loss of nuclear p16 protein expresión correlates with increased tumor cell proliferation (Ki-67) and poor prognosis in patients with vertical growth phase melanoma. *Vlin Case Res* 2000; 6: 1845-1853.

Tang A, Eller MS, Hara M, Yaars S, Hirohashi S, Gilrest BA. E-cadheín is the major mediator of human melanocyte adhesion to keratynocytes in vitro. *J Cell Sci*, 1994; 107:983-992.

Takata M, Matsui Y. Proliferating cell nuclear antigen (PCNA) and p53 protein expression in Bowens's disease. *J Dermatol* 1994; 21: 947-952.

Thorn M, Adami HO, Ringborg U, Bergstrom R, Krusemo U. The association between anatomic site and survival in malignant melanoma. An analysis of 12. 353 cases from the Swedish Cancer Registry. *Eur J Cancer Clin Oncol* 1989; 25: 483-491.

Thune I, Olsen A, Albrektsen G, Tretli S. Cutaneous malignant melanoma: association with height, weight and body surface area. A prospective study in Norway. *Int J Cancer* 1993; 55: 555-561.

Trent JM, Meyskerns FL, Salmon SE Ryschon K, Leong SP; Davis JR. Relations of cytogenetic abnormalities and clinical outcome in metastatic melanoma. *N Engl J Med*, 1990; 22: 1508-1511.

Tucker MA, Misfeldt D, Coleman CN. Cutaneous malignant melanoma after Hodking's disease. *Ann Intern Med* 1985; 102: 37-41.

Urist MM, Balch CM, Soong SJ, Milton GW, Shaw HM, Mc Govern VJ. Head a neck melanoma in 534 clinical stage I patients: A prognostic factors analysis and results of surgical treatment. *Ann Surg* 1984; 200: 769-775.

Van der Esch EP, Muir CS, Nectoux J. Temporal change in diagnostic criteria as a cause of the increase of malignant melanoma over time is unlikely. *Int J Cancer* 1991; 47: 483-490.

Verheijen R, Kuijpers H, Schlingeman RO, Boehmer A, van Driel R, Brakenhoff G et al. ki-67 detects a nuclear matrix-associated proliferation-related antigen. Intracellular localization during interphase. *J Cell Sci* 1989; 92: 123-130.

Veronesi U, Adams J, Bandiera DC et al. Delayed regional lymph node dissection in stage I malignant melanoma of the skin of the lower extremities. *Cancer* 1982; 49: 2420-2430.

Veronesi U, Cascinelli N. Narrow escisión (1 cm margin) as safe procedure for thin cutaneous melanoma. *Arch Surg* 1991; 126: 438-441.

Vidal Sicart S, Pons F, Piulachs J, Castel T, Palou J, Herranz R. Mid arm sentinel lymph nodes showing surprising drainage from a malignant melanoma in a forearm. *Clin Nucle Med* 1998; 23:273-274.

Vilella R, Castel T. Vacunas en el tratamiento del melanoma: presente y futuro. *Piel* 2001; 16:269-271.

Vlaykova T, Muhonen T, Hahka-Kemppinen M, Phyrhonen S, Jekunen A. Vascularity and prognosis of metastatic melanoma. *Int J Cancer*, 1997; 74: 326-329.

Wallack M, Sivanadham M, Balch C et al. A phase III randomised multi-institutional doubled-blind adjuvant study of vaccina melanoma oncosylate (VMO) vs Vaccinia (V) alone in stage II melanoma (Abstract). *Proc Annu Meet Am Soc Clin Oncol* 1994; 13: 394.

Walter MJ, Ronan SM, Han MC, Beattle CW, Das Gupta TK. Interrelationship between histopathologic characteristics of melanoma and estrogen receptor status. *Cancer* 1991; 68: 184-188.

Wang X, Heller R, Van Voorhis N. detection of submicroscopic lymph nodes metastasis with polymerase chain reaction in patients with malignant melanoma. *Ann Surg* 1994; 220: 768-774.

Wasterdahl J, Ingvar C, Masback A, Jonsson N, Olsson H. Risk of cutaneous malignant melanoma in relation to use of sunbeds: further evidence for UV-A carcinogenicity. *Br J Cancer*, 2000; 82:1593-1599

Weinstock MA, Sober AJ. The risk of progression of lentigo maligna to lentigo maligna melanoma. *Br J Dermatol* 1987; 116: 303-310.

Wells KE, Reitgen DS, Cruse CW. The current management and prognosis of acral lentiginous melanoma. *Ann Plast Surg* 1992; 28: 100.

Whitaker DC, Argenyi Z, Smith AC. Desmoplastic malignant melanoma: rare and difficult to diagnose. *J Am Acad Dermatol* 1992; 26: 704-709.

Whiteman DM, Valery P, McWhirter W, Green AC. Risk factors for childhood melanoma in Queensland, Australia. *Int J Cancer* 1997; 70: 26-31.

Whiteman DC, Parsons PG, Green AC. p53 expression and risk factors for cutaneous melanoma: a case-control study. *Int J Cancer* 1998; 77:843-8.

Wick MM. Skin Cancer. Atlas of Diagnostic Oncology. Dana Faber Cancer Institute, 2nd edition, Arthur T. Skarin. Ed. Mosby-Wolfe, 1996; 11: 358-364.

Woods JE, Soule EH, Borkowski JJ. Experience with malignant melanoma of the head and neck. *Plast Reconstr Surg* 1978; 61: 64-69.

Wong JG, Sterns EE, Kapald KH et al. Prognostic significance of pregnancy in stage I melanoma. *Arch Surg* 1989; 124: 1227-1231.

Yamamoto A. The epidemiology of melanoma in the east. *Melanoma res* 1997; 7(1): 51.

Zanetti R, Rosso R, Faggiano F, Roffino R, Colonna S, Martina G. Etude casetemporelle sur le mélanome de la peau dans la province de Torino, Italie. Rev Epidemiol Santé Publ 1988; 36: 309-317.

Zettersten E, Sagebiel RW, Miller JR, Tallapureddy S, Leong SPL, Kashani Sabet M. Prognostic factors in patients with thick melanoma (>4 mm). Cancer 2002; 94: 1049-1056.